Department of Psychiatry
Penn Behavioral Health

Neuropsychiatry Section

Neuropsychiatry Section

Steve Siegel, MD, PhD

Education/Training

1982-1986   Colgate University, BA, Neuroscience

1990 - 1994  Mount Sinai School of Medicine, PhD, Neurobiology

1988 - 1996   Mount Sinai School of Medicine, MD, Medicine

1996-2000   Hospital of the University of Pennsylvania, Research Residency in Psychiatry


Positions and Employment

1993 - John D. & Catherine T. MacArthur Foundation Training Fellowship

1994 - Charles A. Dana Postdoctoral Training Fellowship

1996-2000 - Wistar Scholar and Residency in Psychiatry, University of Pennsylvania

1999-2001 - Postdoctoral Fellow, Neuropsychiatry, University of Pennsylvania

2001-present - Assistant Professor, Dept. of Psychiatry, University of Pennsylvania School of Medicine


Other Experience and Professional Memberships

1990-present - Member, Society for Neuroscience

1998-present - Member, American Psychiatric Association and license to practice Medicine in State of PA

2001-present - Board Certified in Psychiatry

2001-present - Attending Physician, Hospital of the University of Pennsylvania

2001-present - Member, Association for Academic Psychiatry

2002-present - Member, Society for Biological Psychiatry

2003-present - Associate Member, American College of Neuropsychopharmacology


Honors

2001 - ACNP/ Bristol-Myers Squibb Travel Award

2001 - APA/Kempf Fund Award

2000 - AAP/Bristol-Myers Squibb Fellowship in Academic Psychiatry

2000 - APA/Wyeth-Ayerst M.D. Ph.D. Research Fellowship in Psychiatry

1999 - APA/Organon Excellence in Psychiatry Residency Award

1986 - Honors in Neuroscience, Magna Cum Laude, Phi Beta Kappa, Colgate University

 

Peer-reviewed publications (in chronological order)

  1. Siegel, S. J., Ginsberg, S. D., Hof, P. R., Foote, S. L., Young, W. G., Kraemer, G. W., McKinney, W. T. and Morrison, J. H. Effects of Social Deprivation in Prepubescent Rhesus Monkeys: Immunohistochemical Analysis of the Neurofilament Protein Triplet in the Hippocampal Formation. Brain Res.  619 (1993) 299-305.
  2. Siegel, S. J., Brose, N., Janssen, W. G., Gasic, G. P., Jahn, R., Heinemann, S. F. and Morrison, J. H. Regional, cellular, and ultrastructural distribution of the glutamate receptor subunit NMDAR1 in monkey hippocampus. Proc. Natl. Acad. Sci. USA 91 (1994) 564-568.
  3. Siegel, S. J., Janssen, W. G., Tullai, J. W., Rogers, S. W., Moran, T., Heinemann, S. F. and Morrison, J. H. Distribution of the Excitatory Amino Acid Receptor Subunits GluR2 (4) in Monkey Hippocampus and Colocalization with Subunits GluR5-7 and NMDAR1. J. Neurosci. 15 (1995) 2707-2719.
  4. Gazzaley, A.H., Siegel, S.J., Kordower, J.H., Mufson, E.J. and Morrison, J.H. Circuit-specific alterations of N-methyl-D-aspartate receptor subunit 1 in the dentate gyrus of aged monkeys. Proc. Natl. Acad. Sci. USA 93 (1996) 3121-3125.
  5. Gur, R.C., Ragland, J.D., Moberg, P.J., Turner, T.H., Bilker, W.B., Kohler, C., Siegel, S. J., and Gur R. E. Computerized Neurocognitive Scanning: I. Methodology and validation in healthy people. Neuropsychopharmacology, 25, (2001) 766-776.
  6. Gur, R. C., Ragland, J. D., Moberg, P. J., Bilker, W. B., Kohler, C., Siegel, S. J., and Gur R. E. Computerized Neurocognitive Scanning II:  The Profile of Schizophrenia. Neuropsychopharmacology, 25, (2001) 777-788.
  7. Siegel, S. J., Winey, K., Gur, R. E., Lenox, R. H., Bilker, W. B., Ikeda, D., Gandhi, N., and Zhang, W., A role for surgically implantable long-term antipsychotic delivery systems in the treatment of schizophrenia. Neuropsychopharm, 26/6 (2002) 817-823
  8. Siegel S.J., Connolly P., Liang Y., Lenox R.H., Gur R.E., Bilker W.B., Kanes S.J., Turetsky B.I., The effects of strain, novelty and NMDA blockade on auditory evoked potentials in mice. Neuropsychopharmacology, 2003. 28(4): p. 675-82.
  9. Bilker, W.B, Brensinger, C., Kurtz, M.M., Kohler, C., Gur, R.C., Siegel, S.J., and Gur, R.E., Development of an abbreviated Schizophrenia Quality of Life Scale using a new method. Neuropsychopharmacology, 2003. 28(4): p. 773-7.
  10. Ragland, J.D., Moelter, S. T., McGrath, C., Hill, S. K., Gur, R.E., Bilker, W.B., Siegel, S.J. and Gur, R.C., Levels-Of-Processing Effect on Word Recognition in Schizophrenia, Biol Psychiatry, 2003. 54(11): p. 1154-61.
  11. Kohler CG, Turner TH, Bilker WB, Brensinger CM, Siegel SJ, Kanes SJ, Gur RE, Gur RC (2003) Facial emotion recognition in schizophrenia: intensity effects and error pattern. Am J Psychiatry 160: 1768-74
  12. Connolly PM, Maxwell CR, Kanes SJ, Abel T, Liang Y, Tokarczyk J, Bilker WB, Turetsky BI, Gur RE, Siegel SJ (2003) Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains.Brain Res992:85-95
  13. Gur RE, Kohler C, Ragland JD, Siegel SJ, Bilker WB, Loughead J, Phend N, Gur RC (2003) Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia. Neuropsychopharmacology 28: 2029-36
  14. Moberg PJ, Arnold SE, Doty RL, Kohler C, Kanes S, Siegel S, Gur RE, Turetsky BI (2003) Impairment of odor hedonics in men with schizophrenia. Am J Psychiatry 160: 1784-9
  15. Gelber, E.I., Kohler, C.G., Bilker, W.B., Brensinger, C., Siegel, S.J., Kanes, S.J. and Gur, R.E., Symptom and Demographic Profiles in First-Episode Schizophrenia, Res, 2004. 67(2-3): p. 185-94.
  16. Maxwell CR, Liang Y, Weightman BD, Kanes SJ, Abel T, Gur RE, Turetsky BI, Bilker WB, Lenox RH, Siegel SJ (2004) Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential. Neuropsychopharmacology 29: 739-46
  17. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, Hahn CG, Siegel SJ, Trojanowski JQ, Gur RE, Blake DJ, Arnold SE (2004) Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 113: 1353-63
  18. Irani F, Dankert M, Brensinger C, Bilker WB, Nair SR, Kohler CG, Kanes SJ, Turetsky BI, Moberg PJ, Ragland JD, Gur RC, Gur RE, Siegel SJ (2004) Patient attitudes towards surgically implantable, long-term delivery of psychiatric medicine. Neuropsychopharmacology 29: 960-8
  19. Gur RE, Kohler C, Turetsky BI, Siegel SJ, Kanes SJ, Bilker WB, Brennan AR, Gur RC (2004) A sexually dimorphic ratio of orbitofrontal to amygdala volume is altered in schizophrenia. Biol Psychiatry 55: 512-7
  20. Connolly, P.M., Kanes, S.J, Abel, E, Liang, Y, Maxwell, C, Gur, R.E., and Siegel, S. J., (2004) The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components, Neurochem Res 29, 1179 - 1188
  21. Gould, T.J., Bizily, S.P., Tokarczyk, J., Kelly, M.P., Siegel, S.J, Kanes, S.J., and Abel, T., (2004) Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gs alpha, Neuropsychopharmacology 29 (3) 494-501
  22. Ragland, J.D., Lowrey, N., Indersmitten, T., Kohler, C.G., Kanes, S.J., Siegel, S.J., Gur, R.E., and Gur, R.C., (2004) Relationship Between Semantic Fluency and Verbal Learning in Schizophrenia: Role of Controlled Versus Automatic Processing, American Journal of Psychiatry, 161 (6), 1004-1115
  23. Maxwell CR, Kanes SJ, Abel T, Siegel SJ (2004) Phosphodiesterase inhibitors: A novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129:101-107
  24. Ragland, J.D., Gur, R.C., Valdez, J.N., Loughead, J., Elliott, M., Kohler, C., Kanes, S., Siegel, S.J., Moelter, S.T., Gur, R.E.: Levels-of-processing effect on frontotemporal function in schizophrenia during word encoding and recognition. American Journal of Psychiatry, in press.
  25. Frankel, W.N., Beyer, B., Maxwell, C.R., Pretel, S., Letts V.A., and Siegel, S.J., Development of a new genetic model for absence epilepsy: spike-wave seizures in C3H/He and backcross mice, Journal of Neuroscience., 25(13), 3452-3458.
  26. Siegel, S.J., Maxwell, C.R., Majumdar, S., Trief, D.F., Lerman, C., Gur, R.E.,  Kanes, S.J., and Liang, Y., Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials. Neuroscience, 133, 729-38
  27. Siegel, S.J., Irani, F., Brensinger, C.M., Kohler, C.G., Bilker, W.B., Ragland, J.D., Kanes, S. J.,  Gur, R.C., Gur, R.E., Prognostic variables at intake and long-term level of function in schizophrenia, American Journal of Psychiatry, in press.
  28. Hans, M., Shimoni, K., Danino, D., Siegel, S.J. and Lowman, A., Synthesis and characterization of mpeg-pla prodrug micelles, Biomacromolecules, in press
  29. Budhian, A, Siegel, SJ, Winey, KI, Production of haloperidol loaded PLGA nanoparticles for extended controlled drug release of haloperidol, in press
  30. Maxwell, CR, Ehrlichman, RS, Liang, Y, Gettes, DR, Evans, DL, Kanes, SJ, Abel, T,   Karp, J, Siegel, SJ, Corticosterone modulates auditory gating in mouse, Neuropsychopharmacology, in press
  31. Davis, JA., James, JR, Siegel, SJ, Gould, TJ, Withdrawal from Chronic Nicotine Administration Impairs Contextual Fear Conditioning in C57BL/6 Mice, Journal of  Neuroscience, in press
  32. Roalf, DR., Turetsky, BI, Owzar, K, Balderston, CC, Brensinger, CM, Gur, RE, Siegel, SJ, Moberg, PJ, Unirhinal Olfactory Deficits in Patients with Schizophrenia and First-Degree Relatives, Journal of Neuropsychiatry and Clinical Neurosciences, in press
  33. Maxwell, CR, Liang, Y, Ehrlichman, RS, Trief, D, Majumdar, Kanes, SJ, Karp, J, Siegel, SJ, Ketamine produces lasting disruptions in encoding of sensory stimuli, J Pharmacol Exp Ther, in press
  34. Gur, R.E., Kohler, C.G., Ragland, J.D., Siegel, S.J., Lesko, K., Bilker, W.B., Gur, R.C., Flat Affect in Schizophrenia: Relation to Emotion Processing and Neurocognitive Measures, Schizophrenia Bulletin, In Press.
  35. Metzger, K.L., Maxwell, C.R., Liang, Y., Siegel, S.J. Effects of nicotine vary across two auditory evoked potentials in the mouse. Biol Psychiatry (in press).

Editorials, Reviews and Chapters:

  1. Hans, M.L, Dan, L., Winey, K.I., Lowman, A.M., Siegel, S.J., Daily to Annual Biodegradable Drug Delivery Strategies for Psychoactive Compounds: Handbook of Biodegradable Polymeric Materials & Applications, Edited by S.K. Mallapragada,  American Scientific Publishers, Stevenson Ranch, CA (2004)
  2. Siegel, S. J., Increased patient autonomy through long-term antipsychotic delivery systems in schizophrenia. Exert Rev. Neurotherapeutics 2(6) (2002) 89-91
  3. Morrison, J.H, Siegel, S.J., Gazzaley, A.H., and Huntley, G.W. Glutamate receptors: Emerging links between subunit proteins and specific excitatory circuits in primate hippocampus and neocortex. The Neuroscientist, 2 (1996) 272-283.
  4. Irani, F., Dankert, M. and Siegel, S.J., Patient and family attitudes towards schizophrenia treatment, Current Psychiatry Reports, 6 (4) (2004) 283-8
  5. Siegel, S.J., Extended Release Drug Delivery Strategies in Psychiatry: Theory to Practice, Psychiatry 2005, 2:6 22-31

Animal Models :

  1. Siegel S.J., Connolly P., Liang Y., Lenox R.H., Gur R.E., Bilker W.B., Kanes S.J., Turetsky B.I., The effects of strain, novelty and NMDA blockade on auditory evoked potentials in mice. Neuropsychopharmacology, 2003. 28(4): p. 675-82.
  2. Connolly PM, Maxwell CR, Kanes SJ, Abel T, Liang Y, Tokarczyk J, Bilker WB, Turetsky BI, Gur RE, Siegel SJ (2003) Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains.Brain Res992:85-95
  3. Maxwell CR, Liang Y, Weightman BD, Kanes SJ, Abel T, Gur RE, Turetsky BI, Bilker WB, Lenox RH, Siegel SJ (2004) Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential. Neuropsychopharmacology 29: 739-46
  4. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, Hahn CG, Siegel SJ, Trojanowski JQ, Gur RE, Blake DJ, Arnold SE (2004) Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 113: 1353-63
  5. Connolly, P.M., Kanes, S.J, Abel, E, Liang, Y, Maxwell, C, Gur, R.E., and Siegel, S. J., (2004) The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components, Neurochem Res 29, 1179 - 1188
  6. Gould, T.J., Bizily, S.P., Tokarczyk, J., Kelly, M.P., Siegel, S.J, Kanes, S.J., and Abel, T., (2004) Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gs alpha, Neuropsychopharmacology 29 (3) 494-501
  7. Maxwell CR, Kanes SJ, Abel T, Siegel SJ (2004) Phosphodiesterase inhibitors: A novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129:101-107
  8. Frankel, W.N., Beyer, B., Maxwell, C.R., Pretel, S., Letts V.A., and Siegel, S.J., Development of a new genetic model for absence epilepsy: spike-wave seizures in C3H/He and backcross mice, Journal of Neuroscience., 25(13), 3452-3458.
  9. Siegel, S.J., Maxwell, C.R., Majumdar, S., Trief, D.F., Lerman, C., Gur, R.E., Kanes, S.J., and Liang, Y., Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials. Neuroscience, 133, 729-38
  10. Maxwell, CR, Ehrlichman, RS, Liang, Y, Gettes, DR, Evans, DL, Kanes, SJ, Abel, T, Karp, J, Siegel, SJ, Corticosterone modulates auditory gating in mouse, Neuropsychopharmacology, in press
  11. Davis, JA., James, JR, Siegel, SJ, Gould, TJ, Withdrawal from Chronic Nicotine Administration Impairs Contextual Fear Conditioning in C57BL/6 Mice, Journal of Neuroscience, in press
  12. Maxwell, CR, Liang, Y, Ehrlichman, RS, Trief, D, Majumdar, Kanes, SJ, Karp, J, Siegel, SJ, Ketamine produces lasting disruptions in encoding of sensory stimuli, J Pharmacol Exp Ther, in press
  13. Metzger, K.L., Maxwell, C.R., Liang, Y., Siegel, S.J. Effects of nicotine vary across two auditory evoked potentials in the mouse. Biol Psychiatry (in press)

Long Term Drug Delivery:

  1. Siegel, S. J., Winey, K., Gur, R. E., Lenox, R. H., Bilker, W. B., Ikeda, D., Gandhi, N., and Zhang, W., A role for surgically implantable long-term antipsychotic delivery systems in the treatment of schizophrenia. Neuropsychopharm, 26/6 (2002) 817-823
  2. Irani F, Dankert M, Brensinger C, Bilker WB, Nair SR, Kohler CG, Kanes SJ, Turetsky BI, Moberg PJ, Ragland JD, Gur RC, Gur RE, Siegel SJ (2004) Patient attitudes towards surgically implantable, long-term delivery of psychiatric medicine. Neuropsychopharmacology 29: 960-8
  3. Siegel, S.J., Irani, F., Brensinger, C.M., Kohler, C.G., Bilker, W.B., Ragland, J.D., Kanes, S. J., Gur, R.C., Gur, R.E., Prognostic variables at intake and long-term level of function in schizophrenia, American Journal of Psychiatry, in press.
  4. Hans, M., Shimoni, K., Danino, D., Siegel, S.J. and Lowman, A., Synthesis and characterization of mpeg-pla prodrug micelles, Biomacromolecules, in press
  5. Budhian, A, Siegel, SJ, Winey, KI, Production of haloperidol loaded PLGA nanoparticles for extended controlled drug release of haloperidol, in press
  6. Hans, M.L, Dan, L., Winey, K.I., Lowman, A.M., Siegel, S.J., Daily to Annual Biodegradable Drug Delivery Strategies for Psychoactive Compounds: Handbook of Biodegradable Polymeric Materials & Applications, Edited by S.K. Mallapragada, American Scientific Publishers, Stevenson Ranch, CA (2004)
  7. Siegel, S. J., Increased patient autonomy through long-term antipsychotic delivery systems in schizophrenia. Exert Rev. Neurotherapeutics 2(6) (2002) 89-91
  8. Irani, F., Dankert, M. and Siegel, S.J., Patient and family attitudes towards schizophrenia treatment, Current Psychiatry Reports, 6 (4) (2004) 283-8
  9. Siegel, S.J., Extended Release Drug Delivery Strategies in Psychiatry: Theory to Practice, Psychiatry 2005, 2:6 22-31